COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States
Background and Aims: The change in hepatocellular carcinoma (HCC) care continuum during the coronavirus disease 2019 (COVID-19) pandemic remains unknown at a national level in the United States. We sought to determine the impact of the pandemic on incident HCC cases, clinical characteristics, and tr...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Gastro Hep Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772572323001863 |
| _version_ | 1827341719542169600 |
|---|---|
| author | Bhupinder Kaur Yee Hui Yeo Jeff Liang Michael Luu Walid Ayoub Alexander Kuo Hirsh Trivedi Kamya Sankar Jun Gong Andrew Hendifar Arsen Osipov Kambiz Kosari Nicholas Nissen Mazen Noureddin Amit G. Singal Ju Dong Yang |
| author_facet | Bhupinder Kaur Yee Hui Yeo Jeff Liang Michael Luu Walid Ayoub Alexander Kuo Hirsh Trivedi Kamya Sankar Jun Gong Andrew Hendifar Arsen Osipov Kambiz Kosari Nicholas Nissen Mazen Noureddin Amit G. Singal Ju Dong Yang |
| author_sort | Bhupinder Kaur |
| collection | DOAJ |
| description | Background and Aims: The change in hepatocellular carcinoma (HCC) care continuum during the coronavirus disease 2019 (COVID-19) pandemic remains unknown at a national level in the United States. We sought to determine the impact of the pandemic on incident HCC cases, clinical characteristics, and treatment in the United States. Methods: Using the National Cancer Database, we analyzed incident HCC cases from 2010 to 2020. The incidence rate was calculated using the population data for each year from the census bureau. Joinpoint regression analysis was applied for trend analysis, and a polynomial regression model estimated the number of projected HCC cases in 2020 according to the trend of rates from 2010 to 2019. The distribution of cancer stage and treatment modality were assessed. Results: The pandemic led to a significant reduction in reported HCC cases, from 19,597 in 2019 to 16,188 in 2020. The projected number of HCC for 2020 was 19,011, corresponding to a 14.8% reduction in 2020. Extent of reduction in the number of incident HCC cases relative to estimated cases remains consistent in racial and ethnic subgroups. Despite underdiagnosis of HCC in 2020, proportion of patients with early tumor stage (30.5% for Tumour, Node, Metastasis stage 1) and curative treatment receipt (9.1% for surgical resection, 13% for ablation, 4.2% for liver transplant) for HCC remained stable in the first year of the COVID-19 pandemic. Conclusion: There was a significant reduction in HCC cases in 2020 compared to pre-COVID years. While tumor stage and proportion of patients receiving curative treatment remained stable, continued follow-up is needed to assess potential changes during subsequent years. |
| first_indexed | 2024-03-07T21:52:09Z |
| format | Article |
| id | doaj.art-344988ee4f5e4b03989b5222e9cc73fc |
| institution | Directory Open Access Journal |
| issn | 2772-5723 |
| language | English |
| last_indexed | 2024-03-07T21:52:09Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gastro Hep Advances |
| spelling | doaj.art-344988ee4f5e4b03989b5222e9cc73fc2024-02-25T04:36:44ZengElsevierGastro Hep Advances2772-57232024-01-0132230237COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United StatesBhupinder Kaur0Yee Hui Yeo1Jeff Liang2Michael Luu3Walid Ayoub4Alexander Kuo5Hirsh Trivedi6Kamya Sankar7Jun Gong8Andrew Hendifar9Arsen Osipov10Kambiz Kosari11Nicholas Nissen12Mazen Noureddin13Amit G. Singal14Ju Dong Yang15Division of Internal Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CaliforniaDivision of Internal Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California; Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CaliforniaDivision of Internal Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CaliforniaBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, CaliforniaKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CaliforniaKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CaliforniaKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CaliforniaSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CaliforniaSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CaliforniaSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CaliforniaSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CaliforniaSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California; Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CaliforniaSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California; Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CaliforniaDepartment of Medicine, Houston Methodist Lynda K. & David M. Underwood Center for Digestive Disorder, Houston, TexasDivision of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas; Department of Population & Data Sciences, UT Southwestern Medical Center, Dallas, TexasKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California; Correspondence: Address correspondence to: Ju Dong Yang, MD, MS, Liver Cancer Program, Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, California 90048.Background and Aims: The change in hepatocellular carcinoma (HCC) care continuum during the coronavirus disease 2019 (COVID-19) pandemic remains unknown at a national level in the United States. We sought to determine the impact of the pandemic on incident HCC cases, clinical characteristics, and treatment in the United States. Methods: Using the National Cancer Database, we analyzed incident HCC cases from 2010 to 2020. The incidence rate was calculated using the population data for each year from the census bureau. Joinpoint regression analysis was applied for trend analysis, and a polynomial regression model estimated the number of projected HCC cases in 2020 according to the trend of rates from 2010 to 2019. The distribution of cancer stage and treatment modality were assessed. Results: The pandemic led to a significant reduction in reported HCC cases, from 19,597 in 2019 to 16,188 in 2020. The projected number of HCC for 2020 was 19,011, corresponding to a 14.8% reduction in 2020. Extent of reduction in the number of incident HCC cases relative to estimated cases remains consistent in racial and ethnic subgroups. Despite underdiagnosis of HCC in 2020, proportion of patients with early tumor stage (30.5% for Tumour, Node, Metastasis stage 1) and curative treatment receipt (9.1% for surgical resection, 13% for ablation, 4.2% for liver transplant) for HCC remained stable in the first year of the COVID-19 pandemic. Conclusion: There was a significant reduction in HCC cases in 2020 compared to pre-COVID years. While tumor stage and proportion of patients receiving curative treatment remained stable, continued follow-up is needed to assess potential changes during subsequent years.http://www.sciencedirect.com/science/article/pii/S2772572323001863Coronavirus Disease 2019 (COVID-19)Liver CancerUnderdiagnosisUnited States |
| spellingShingle | Bhupinder Kaur Yee Hui Yeo Jeff Liang Michael Luu Walid Ayoub Alexander Kuo Hirsh Trivedi Kamya Sankar Jun Gong Andrew Hendifar Arsen Osipov Kambiz Kosari Nicholas Nissen Mazen Noureddin Amit G. Singal Ju Dong Yang COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States Gastro Hep Advances Coronavirus Disease 2019 (COVID-19) Liver Cancer Underdiagnosis United States |
| title | COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States |
| title_full | COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States |
| title_fullStr | COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States |
| title_full_unstemmed | COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States |
| title_short | COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States |
| title_sort | covid 19 pandemic impact on diagnosis stage and treatment of hepatocellular carcinoma in the united states |
| topic | Coronavirus Disease 2019 (COVID-19) Liver Cancer Underdiagnosis United States |
| url | http://www.sciencedirect.com/science/article/pii/S2772572323001863 |
| work_keys_str_mv | AT bhupinderkaur covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT yeehuiyeo covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT jeffliang covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT michaelluu covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT walidayoub covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT alexanderkuo covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT hirshtrivedi covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT kamyasankar covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT jungong covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT andrewhendifar covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT arsenosipov covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT kambizkosari covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT nicholasnissen covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT mazennoureddin covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT amitgsingal covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates AT judongyang covid19pandemicimpactondiagnosisstageandtreatmentofhepatocellularcarcinomaintheunitedstates |